Insights on Duo-E Trial: Advancing Endometrial Cancer Treatment with Olaparib
Listen to Shannon Westin explaining the findings from the Duo-E trial, shedding light on a significant progression-free survival enhancement, particularly with olaparib inclusion. The trial focused on patients with recurrent or advanced-stage endometrial cancer who had not received prior therapy or had adjuvant therapy with chemotherapy. The addition of olaparib to the treatment appears to be beneficial, especially for patients with mismatch repair deficient disease.
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.